CSL Biotherapies Inc. renamed bioCSL Inc.

                  CSL Biotherapies Inc. renamed bioCSL Inc.

bioCSL Inc. initiates 2014-15 season pre-booking for AFLURIA® (Influenza
Vaccine)

PR Newswire

KING OF PRUSSIA, Pa., Feb. 27, 2014

KING OF PRUSSIA, Pa., Feb. 27, 2014 /PRNewswire/ --CSL Biotherapies Inc.
announced today it has changed its name to bioCSL Inc., effective February 21,
2014. This change is pursuant to the Australian, New Zealand and German
renaming of the company, which occurred one year ago.

In September 2013, bioCSL was the first United States supplier to complete its
2013-14 seasonal influenza vaccine delivery campaign, which consisted of more
than 11 million doses of AFLURIA® (Influenza Vaccine) delivered to the United
States marketplace.

In addition to the name change for the U.S. entity, the company has initiated
pre-ordering of AFLURIA for the 2014-15 season through national distributors
and with order requests received via the brand's website, www.afluria.com.

"We are excited about serving the needs of our customers with our new US
sales, marketing, and operations team. To date, we have received highly
favorable comments from customers and business partners who recognize AFLURIA®
as an important influenza vaccine choice due to its reliable and timely
delivery performance this year," said Dr. Marie Mazur, President of bioCSL
Inc.

About AFLURIA®
AFLURIA® is an inactivated influenza vaccine indicated for active immunization
against influenza disease caused by influenza virus subtypes A and type B
present in the vaccine. AFLURIA is approved for use in persons 5 years of age
and older.

Select Safety Information
AFLURIA is contraindicated in individuals with known severe allergic reactions
(eg, anaphylaxis) to any component of the vaccine including egg protein, or to
a previous dose of any influenza vaccine. Administration of CSL's 2010
Southern Hemisphere influenza vaccine was associated with post-marketing
reports of increased rates of fever and febrile seizures in children
predominantly below the age of 5 years as compared to previous years; these
increased rates were confirmed by post-marketing studies. Febrile events were
also observed in children 5 to less than 9 years of age. If Guillain-Barre
Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination,
the decision to give AFLURIA should be based on careful consideration of the
potential benefits and risks. If AFLURIA is administered to immunocompromised
persons, including those receiving immunosuppressive therapy, the immune
response may be diminished. AFLURIA should be given to a pregnant woman only
if clearly needed. AFLURIA has not been evaluated in nursing mothers. It is
not known whether AFLURIA is excreted in human milk. Because many drugs are
excreted in human milk, caution should be exercised when AFLURIA is
administered to a nursing woman. Antibody responses in persons 65 years of age
and older were lower after administration of AFLURIA as compared to younger
adult subjects. In children 5 through 17 years of age, the most common
injection-site reactions observed in clinical studies with AFLURIA were pain,
redness, and swelling. The most common systemic adverse events were headache,
myalgia, malaise, and fever. In adults 18 through 64 years of age, the most
common injection-site adverse reactions observed in clinical studies with
AFLURIA were tenderness and pain. The most common systemic adverse reactions
observed were headache, malaise, and muscle aches. In adults 65 years of age
and older, the most common injection-site adverse reactions observed in
clinical studies with AFLURIA were tenderness and pain. Vaccination with
AFLURIA may not protect all individuals. Before administering AFLURIA, please
read the Prescribing Information.

About bioCSL Inc.
bioCSL Inc., located in King of Prussia, Pennsylvania, is the United States
headquarters of bioCSL. Parent company, CSL Limited, has manufactured
influenza vaccine in its Melbourne, Australia, facility since 1968. CSL
Limited has made a $60 million (U.S.D.) investment in plant and equipment to
double capacity at its Melbourne facility, making it one of the largest
vaccine manufacturing facilities in the world. CSL-branded influenza vaccines
are approved in 28 countries. At bioCSL Inc., delivering vaccines is our
mission, protecting lives our passion.The CSL Group, which also includes CSL
Research & Development, CSL Plasma, and CSL Behring, has more than 11,000
employees globally and operates in 26 countries around the world.

Media Contact:
Sheila Burke
610-290-7403

Sales & Marketing Contact
Chris Woolway
610-290-7420

SOURCE bioCSL Inc.

Website: http://www.afluria.com
 
Press spacebar to pause and continue. Press esc to stop.